Page 11 - Oche News Today

Chemed Co. (NYSE:CHE – Get Free Report) announced a quarterly dividend on Monday, November 6th, Wall Street Journal reports. Investors of record on Monday, November 13th will be given a dividend of 0.40 per share on Monday, December 4th. This represents a $1.60 annualized dividend and a dividend yield of 0.27%. The ex-dividend date is […]

Chemed (NYSE:CHE – Free Report) had its price target increased by Royal Bank of Canada from $576.00 to $604.00 in a research note released on Monday, Benzinga reports. They currently have an outperform rating on the stock. Separately, StockNews.com assumed coverage on shares of Chemed in a research note on Thursday, October 5th. They set […]

Smith Salley & Associates increased its holdings in Chemed Co. (NYSE:CHE – Free Report) by 0.5% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,397 shares of the company’s stock after purchasing an additional 95 shares during the period. Smith Salley & Associates owned approximately […]

On Sunday, the clocks are turned back and we gain an hour in our life thanks to the end of Daylight Saving Time. It’s tough in March when we “spring”

Chemed Co. (NYSE:CHE – Get Free Report) CEO Kevin J. Mcnamara sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $560.68, for a total value of $2,803,400.00. Following the completion of the transaction, the chief executive officer now directly owns 112,968 […]

Handelsbanken Fonder AB grew its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 20.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 2,372 shares of the company’s stock after acquiring an additional 400 shares during the period. Handelsbanken Fonder AB’s holdings in Chemed were […]

Education

Last weekend I was able to see what might be one of the nation’s finest monuments on its way to its final destination in Brigham City, Utah. My daughter, Natalie,

Pfizer will still benefit from the 25% stake it retained as well as full rights to the drug outside the US and Japan.

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Sch...